The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma
Background: The optimal conditioning regimen of tandem high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NBL) has not been established. The efficacy of <sup>131</sup>I-MIBG therapy is under exploration in newly diagnosed HR-NBL p...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/10/12/1936 |
| _version_ | 1797381590236528640 |
|---|---|
| author | Hyun Jin Park Jung Yoon Choi Bo Kyung Kim Kyung Taek Hong Hyun-Young Kim Il Han Kim Gi Jeong Cheon Jung-Eun Cheon Sung-Hye Park Hyoung Jin Kang |
| author_facet | Hyun Jin Park Jung Yoon Choi Bo Kyung Kim Kyung Taek Hong Hyun-Young Kim Il Han Kim Gi Jeong Cheon Jung-Eun Cheon Sung-Hye Park Hyoung Jin Kang |
| author_sort | Hyun Jin Park |
| collection | DOAJ |
| description | Background: The optimal conditioning regimen of tandem high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NBL) has not been established. The efficacy of <sup>131</sup>I-MIBG therapy is under exploration in newly diagnosed HR-NBL patients. Here, we compared the outcomes of tandem HDC/ASCT between the <sup>131</sup>I-MIBG combination and non-MIBG groups. Methods: We retrospectively analyzed the clinical data of 33 HR-NBL patients who underwent tandem HDC/ASCT between 2007 and 2021 at the Seoul National University Children’s Hospital. Results: The median age at diagnosis was 3.6 years. <sup>131</sup>I-MIBG was administered to 13 (39.4%) of the patients. Thirty patients (90.9%) received maintenance therapy after tandem HDC/ASCT, twenty-two were treated with isotretinoin ± interleukin-2, and eight received salvage chemotherapy. The five-year overall survival (OS) and event-free survival (EFS) rates of all patients were 80.4% and 69.4%, respectively. Comparing the <sup>131</sup>I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (<i>p</i> = 0.655), and the five-year EFS rates were 69.2% and 69.6% (<i>p</i> = 0.922), respectively. Among the adverse effects of grade 3 or 4, the incidence of liver enzyme elevation was significantly higher in the non-<sup>131</sup>I-MIBG group. Conclusions: Although tandem HDC/ASCT showed promising outcomes, the <sup>131</sup>I-MIBG combination did not improve survival rates. |
| first_indexed | 2024-03-08T20:53:36Z |
| format | Article |
| id | doaj.art-51ca4b2236d04b599dcbf1fee6e9b860 |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-08T20:53:36Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-51ca4b2236d04b599dcbf1fee6e9b8602023-12-22T14:00:33ZengMDPI AGChildren2227-90672023-12-011012193610.3390/children10121936The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk NeuroblastomaHyun Jin Park0Jung Yoon Choi1Bo Kyung Kim2Kyung Taek Hong3Hyun-Young Kim4Il Han Kim5Gi Jeong Cheon6Jung-Eun Cheon7Sung-Hye Park8Hyoung Jin Kang9Department of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pediatric Surgery, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaSeoul National University Cancer Research Institute, Seoul 03080, Republic of KoreaSeoul National University Cancer Research Institute, Seoul 03080, Republic of KoreaDepartment of Radiology, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pathology, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaDepartment of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of KoreaBackground: The optimal conditioning regimen of tandem high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NBL) has not been established. The efficacy of <sup>131</sup>I-MIBG therapy is under exploration in newly diagnosed HR-NBL patients. Here, we compared the outcomes of tandem HDC/ASCT between the <sup>131</sup>I-MIBG combination and non-MIBG groups. Methods: We retrospectively analyzed the clinical data of 33 HR-NBL patients who underwent tandem HDC/ASCT between 2007 and 2021 at the Seoul National University Children’s Hospital. Results: The median age at diagnosis was 3.6 years. <sup>131</sup>I-MIBG was administered to 13 (39.4%) of the patients. Thirty patients (90.9%) received maintenance therapy after tandem HDC/ASCT, twenty-two were treated with isotretinoin ± interleukin-2, and eight received salvage chemotherapy. The five-year overall survival (OS) and event-free survival (EFS) rates of all patients were 80.4% and 69.4%, respectively. Comparing the <sup>131</sup>I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (<i>p</i> = 0.655), and the five-year EFS rates were 69.2% and 69.6% (<i>p</i> = 0.922), respectively. Among the adverse effects of grade 3 or 4, the incidence of liver enzyme elevation was significantly higher in the non-<sup>131</sup>I-MIBG group. Conclusions: Although tandem HDC/ASCT showed promising outcomes, the <sup>131</sup>I-MIBG combination did not improve survival rates.https://www.mdpi.com/2227-9067/10/12/1936neuroblastomaautologous stem cell transplantationchemotherapypediatrics |
| spellingShingle | Hyun Jin Park Jung Yoon Choi Bo Kyung Kim Kyung Taek Hong Hyun-Young Kim Il Han Kim Gi Jeong Cheon Jung-Eun Cheon Sung-Hye Park Hyoung Jin Kang The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma Children neuroblastoma autologous stem cell transplantation chemotherapy pediatrics |
| title | The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma |
| title_full | The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma |
| title_fullStr | The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma |
| title_full_unstemmed | The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma |
| title_short | The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma |
| title_sort | impact of sup 131 sup i metaiodobenzylguanidine as a conditioning regimen of tandem high dose chemotherapy and autologous stem cell transplantation for high risk neuroblastoma |
| topic | neuroblastoma autologous stem cell transplantation chemotherapy pediatrics |
| url | https://www.mdpi.com/2227-9067/10/12/1936 |
| work_keys_str_mv | AT hyunjinpark theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT jungyoonchoi theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT bokyungkim theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT kyungtaekhong theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT hyunyoungkim theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT ilhankim theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT gijeongcheon theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT jungeuncheon theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT sunghyepark theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT hyoungjinkang theimpactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT hyunjinpark impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT jungyoonchoi impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT bokyungkim impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT kyungtaekhong impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT hyunyoungkim impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT ilhankim impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT gijeongcheon impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT jungeuncheon impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT sunghyepark impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma AT hyoungjinkang impactofsup131supimetaiodobenzylguanidineasaconditioningregimenoftandemhighdosechemotherapyandautologousstemcelltransplantationforhighriskneuroblastoma |